Six The phosphodiesterase-5 inhibitor sildenafil is accredited for PAH in FC I–IV from the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies accredited for use in PAH. As no oral agent has shown superiority there remains debate https://tracleer35689.activablog.com/25872858/facts-about-bosentan-revealed